April 18, 2025
The US Food and Drug Administration (FDA) has granted marketing authorization to CT-132 (Click Therapeutics), an adjunctive, first-in-class prescription digital therapeutic for the preventive treatment of […]
April 17, 2025
A new systematic review has identified 17 modifiable risk factors shared by at least two of three major age-related brain disorders — stroke, dementia, and late-life […]
April 17, 2025
Two early-stage clinical trials demonstrate the safety and potential effectiveness of stem cell therapies to treat Parkinson’s disease (PD), the second most common neurological disease worldwide. […]
April 16, 2025
Twenty-five years ago, stroke care in the United States was fragmented, and hospitals, for the most part, weren’t adhering to evidence-based guidelines. The majority of stroke […]
April 16, 2025
SAN DIEGO — The investigational drug AXS-12 (reboxetine, Axsome Therapeutics) is safe and effective for the treatment of cataplexy (emotionally induced muscle weakness) and excessive daytime […]
April 15, 2025
SAN DIEGO — Tavapadon, a novel and highly selective partial agonist of dopamine D1 and D5 receptors, significantly improved motor function without increasing impulse control disorders […]
April 15, 2025
TOPLINE: US hospitalizations related to cervical artery dissection (CeAD) increased more than fourfold between 2005 and 2019, suggested a new study that also showed vertebral artery […]
April 15, 2025
TOPLINE: Poor oral health was associated with increased migraines and abdominal and body pain in women with central sensitization disorders, with risk for specific pain conditions […]
April 14, 2025
The US Food and Drug Administration (FDA) has approved a prefilled syringe for self-injection of efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo, argenx) in the treatment of […]